Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Anesthesiol ; 17(1): 130, 2017 Sep 20.
Article in English | MEDLINE | ID: mdl-28931374

ABSTRACT

BACKGROUND: Dexmedetomidine is a highly selective adrenergic receptor agonist, which has a dose-dependent sedative hypnotic effect. Furthermore, it also has pharmacological properties, and the ability to inhibit sympathetic activity and improve cardiovascular stability during an operation. However, its protective effect on patients with severe craniocerebral injury in the perioperative period remains unclear. METHOD: Eighty adult male SD rats were used and divided into two groups (n = 40, each group): dexmedetomidine injury group (experimental group), and sodium chloride injury group (control group). Models of severe craniocerebral injury were established in these two groups using the modified Feeney's free-fall method. As soon as the establishment of models was succeed, rat in the experimental group received 1 µg of dexmedetomidine (0.1 ml), while each rat in the control group was given 0.1 ml of 0.9% sodium chloride. Blood was sampled from an incision at the femoral vein to detect TNF-α and IL-2 levels at 1, 12, 24,36,48 and 72 h after establishing the model in the two groups. RESULTS: After severe craniocerebral injury, TNF-α levels of rats were lower in every stage and at different degrees in the experimental group than in the control group (P < 0.05), while IL-2 levels were lower in the experimental group to different extents (P < 0.05). CONCLUSION: Dexmedetomidine protects the brain of rats with severe craniocerebral injury by reducing the release of inflammatory mediators.


Subject(s)
Adrenergic alpha-2 Receptor Agonists/therapeutic use , Craniocerebral Trauma/blood , Craniocerebral Trauma/drug therapy , Dexmedetomidine/therapeutic use , Interleukin-2/blood , Tumor Necrosis Factor-alpha/blood , Adrenergic alpha-2 Receptor Agonists/pharmacology , Animals , Biomarkers/blood , Dexmedetomidine/pharmacology , Interleukin-2/antagonists & inhibitors , Male , Rats , Rats, Sprague-Dawley , Severity of Illness Index , Tumor Necrosis Factor-alpha/antagonists & inhibitors
2.
Medicine (Baltimore) ; 96(31): e7519, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28767570

ABSTRACT

This study aims to explore the effect of oxycodone hydrochloride injection on the immune function of patients who underwent radical resection of rectal cancer under general anesthesia.Eighty patients were enrolled and randomly divided into group A and B (n = 40, each). All patients underwent general intravenous anesthesia. At the end of surgery, each patient in group A was injected with 5 mg (5 mL) of oxycodone hydrochloride, while 5 mg (5 mL) of morphine hydrochloride in group B. Venous blood was withdrawn in both groups at different time points. Changes in the numbers of T lymphocyte subsets and natural killer (NK) cells were determined by flow cytometry.First the numbers of T lymphocyte subsets and NK cells at T1, T2, T3, and T4 decreased in both groups, compared with those at T0, and the differences were statistically significant. Furthermore, the numbers reduced to a minimum at T2 and began to recover at T3. Second the differences between group A and B at T1, T2, T3, and T4 were statistically significant; and the numbers of T lymphocytes and NK cells were higher in group A than in group B at corresponding time points.Oxycodone hydrochloride and morphine hydrochloride both have inhibitory effects on immune function in patients undergoing radical resection of rectal cancer after surgery. However, oxycodone hydrochloride has a smaller effect compared to morphine hydrochloride.


Subject(s)
Analgesics, Opioid/therapeutic use , Anesthesia, General , Oxycodone/therapeutic use , Rectal Neoplasms/drug therapy , Rectal Neoplasms/surgery , Analgesics, Opioid/adverse effects , Biomarkers/blood , Female , Humans , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , Male , Middle Aged , Morphine/therapeutic use , Oxycodone/adverse effects , Rectal Neoplasms/blood , Rectal Neoplasms/immunology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...